APLLTD.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 09:18):

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations...

Stats
Šios dienos apimtis	38 321.00
Vidutinė apimtis	173 633
Rinkos kapitalizacija	195.62B
EPS	INR0 ( 2024-04-04 )
Kita pelno data	( INR6.90 ) 2024-05-08
Last Dividend	INR8.00 ( 2023-07-28 )
Next Dividend	INR0 ( N/A )
P/E	33.17
ATR14	INR0.966 (0.10%)

Tūris Koreliacija

Ilgas: 0.08 (neutral)

Trumpas: 0.18 (neutral)

Signal:(53.784) Neutral

Alembic Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
KRITIKA.NS	0.931
ICICIPHARM.NS	0.93
KOPRAN.NS	0.929
NAVNETEDUL.NS	0.923
MUTHOOTFIN.NS	0.921
STAR.NS	0.919
FAIRCHEMOR.NS	0.912
KCP.NS	0.908
AARTISURF.NS	0.907
20MICRONS.NS	0.907

10 Labiausiai neigiamai susiję koreliacijos
LTGILTBEES.NS	-0.938
4THDIM.NS	-0.936
RAJRILTD.NS	-0.93
JSL.NS	-0.893
ACI.NS	-0.864
GNA.NS	-0.858
SYMPHONY.NS	-0.853
ISMTLTD.NS	-0.849
DFMFOODS.NS	-0.834
GTNIND.NS	-0.817

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Alembic Pharmaceuticals Koreliacija - Valiuta/Žaliavos

0.30
( neutral )

0.42
( neutral )

0.29
( neutral )

-0.25
( neutral )

-0.09
( neutral )

-0.79
( moderate negative )

Alembic Pharmaceuticals Finansinės ataskaitos

Annual	2022
Pajamos:	INR56.53B
Bruto pelnas:	INR39.44B (69.77 %)
EPS:	INR17.40

FY	2022
Pajamos:	INR56.53B
Bruto pelnas:	INR39.44B (69.77 %)
EPS:	INR17.40

FY	2022
Pajamos:	INR52.32B
Bruto pelnas:	INR35.09B (67.06 %)
EPS:	INR26.50

FY	2021
Pajamos:	INR53.01B
Bruto pelnas:	INR37.80B (71.30 %)
EPS:	INR60.81

Financial Reports:

No articles found.

Alembic Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR10.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR8.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Alembic Pharmaceuticals Dividend Information - Dividend Junior

Dividend Sustainability Score: 3.28 - low (9.11%) | Divividend Growth Potential Score: 3.89 - Decrease likely (22.17%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR1.400	2012-07-31
Last Dividend	INR8.00	2023-07-28
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	12	--
Total Paid Out	INR62.90	--
Avg. Dividend % Per Year	0.84%	--
Score	2.03	--
Div. Sustainability Score	3.28
Div.Growth Potential Score	3.89
Div. Directional Score	3.58	--

Next Divdend (Est)
(2024-06-27)

INR8.06 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.03

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR4.00	0.79%
2019	INR5.50	0.94%
2020	INR3.00	0.55%
2021	INR14.00	1.34%
2022	INR10.00	1.24%
2023	INR8.00	1.41%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TIDEWATER.NS	Dividend Knight	2023-07-04	Semi-Annually	18	2.24%
PAISALO.NS	Dividend Junior	2023-09-14	Annually	16	0.10%
ITDC.NS	Dividend Junior	2023-09-20	Sporadic	8	0.17%
DAAWAT.NS	Dividend Junior	2023-09-21	Annually	18	1.02%
SHREYANIND.NS	Dividend Junior	2023-08-03	Annually	12	1.43%
MASFIN.NS	Dividend Junior	2023-07-19	Annually	8	0.28%
GRPLTD.NS	Dividend Junior	2023-07-28	Annually	10	0.46%
BANARISUG.NS	Dividend Junior	2023-08-28	Annually	22	0.34%
POWERINDIA.NS	Dividend Junior	2023-08-10	Annually	4	0.07%
JUBLINGREA.NS	Dividend Junior	2023-08-10	Semi-Annually	4	0.47%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0965	1.500	8.07	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.134	1.500	9.63	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	10.28	1.000	7.30	7.30	[3 - 30]
operatingCashFlowPerShareTTM	28.22	2.00	0.595	1.189	[0 - 30]
freeCashFlowPerShareTTM	28.22	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.711	1.000	1.484	1.484	[0.2 - 0.8]
operatingProfitMarginTTM	0.100	1.000	10.00	10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.28

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	32.98	1.000	6.77	0	[1 - 100]
returnOnEquityTTM	0.134	2.50	9.76	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	28.22	2.00	0.595	10.00	[0 - 30]
dividendYielPercentageTTM	0.808	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	28.22	2.00	0.595	1.189	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.630	1.500	9.13	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0907	1.000	-0.234	0	[0.1 - 0.5]
Total Score				3.89

Alembic Pharmaceuticals

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, and anti-diabetic. In addition, it exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.